Hikma Pharmaceuticals Plc (LON:HIK) had its target price reduced by Jefferies Group from GBX 2,500 ($31.23) to GBX 2,000 ($24.99) in a research report issued on Friday. The brokerage presently has a “buy” rating on the stock. Jefferies Group’s price target suggests a potential upside of 23.15% from the stock’s previous close.

A number of other research firms have also recently issued reports on HIK. Numis Securities Ltd cut shares of Hikma Pharmaceuticals Plc to a “hold” rating and set a GBX 2,660 ($33.23) price objective on the stock. in a research report on Thursday, August 4th. JPMorgan Chase & Co. cut their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,800 ($34.98) to GBX 2,550 ($31.86) and set an “overweight” rating on the stock in a research report on Thursday, August 4th. Barclays PLC reissued an “overweight” rating and set a GBX 2,800 ($34.98) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 4th. Citigroup Inc. cut shares of Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($32.48) price objective on the stock. in a research report on Thursday, August 4th. Finally, Morgan Stanley began coverage on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, July 21st. They set an “equal weight” rating and a GBX 2,700 ($33.73) price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of GBX 2,337.40 ($29.20).

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Hikma Pharmaceuticals Plc (LON:HIK) opened at 1724.00 on Friday. The firm’s market cap is GBX 3.90 billion. The firm’s 50-day moving average price is GBX 1,893.92 and its 200-day moving average price is GBX 2,205.15. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,575.00 and a 12 month high of GBX 2,703.00.

In other Hikma Pharmaceuticals Plc news, insider Darwazah,Mazen purchased 155,991 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were acquired at an average price of GBX 2,194 ($27.41) per share, with a total value of £3,422,442.54 ($4,275,915.22). Also, insider Darwazah,Said purchased 200,000 shares of the company’s stock in a transaction that occurred on Friday, August 26th. The stock was acquired at an average cost of GBX 2,160 ($26.99) per share, for a total transaction of £4,320,000 ($5,397,301.35).

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.